Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Johnson & Johnson (JNJ) AI Forecast

Our AI detected a significant signal for Johnson & Johnson. Create a free account and follow it to see the exact price target.

Free account • 30-day free trial

$JNJ Bullish Signal Full forecast available

Johnson & Johnson (JNJ) Stock Forecast 2025


Johnson & Johnson (JNJ) AI Stock Price Forecast & Investment Analysis

Johnson & Johnson Stock Price Chart and Technical Analysis

Loading chart...

Johnson & Johnson (JNJ) - Comprehensive Stock Analysis & Investment Research

Deep dive into Johnson & Johnson's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 28, 2026, 11:58 p.m. (UTC)

Johnson & Johnson Investment Summary

When evaluating whether Johnson & Johnson (JNJ) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Johnson & Johnson (JNJ) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $640 billion, the company is classified as a mega-cap stock, typically characterized by high stability and strong institutional backing.

Financial Performance Analysis

Our comprehensive financial analysis covers Johnson & Johnson's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Johnson & Johnson along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Johnson & Johnson is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Johnson & Johnson

Sign Up Free
Corporate Identity

Johnson & Johnson (Stock Symbol: JNJ) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Johnson & Johnson's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Johnson & Johnson...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Johnson & Johnson...

Unlock Full Company Profile

Get complete details about Johnson & Johnson

Sign Up Free
Revenue & Growth Analysis

Johnson & Johnson generates annual revenues of $98 billion , demonstrating substantial market presence and operational scale.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Johnson & Johnson...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Johnson & Johnson...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Johnson & Johnson...

Unlock Financial Analysis

Get complete financial metrics for Johnson & Johnson

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Johnson & Johnson's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Johnson & Johnson strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mega-cap market leader, the company commands significant market influence, enjoying substantial competitive moats including brand recognition, scale economies, and extensive distribution networks. Mega-cap status typically brings advantages in capital access, talent acquisition, and partnership opportunities, while also attracting the highest levels of institutional investor and analyst coverage.

Industry Competitive Landscape

Johnson & Johnson competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company demonstrates exceptional operational efficiency through free cash flow generation of $22 billion annually . This substantial cash generation capability provides significant strategic flexibility for acquisitions, share repurchases, dividend growth, or debt reduction—all while maintaining operational investments necessary to defend market position.

Margin & Pricing Power Analysis

The company maintains a 71.3% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Asset Utilization Efficiency

Asset turnover ratio of 0.49x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 1.09 suggests tight liquidity where current assets just cover current liabilities. This may be efficient but leaves limited cushion for unexpected needs.

Johnson & Johnson (JNJ) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Johnson & Johnson stock analysis.

Deep dive into Johnson & Johnson's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Johnson & Johnson stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Johnson & Johnson: With a P/E ratio of 30.43, the market highly values future growth prospects.

P/E Ratio 30.43x
P/B Ratio 7.54x
Market Cap $640.25B
Dividend Yield 1.97%
EPS $9.64
Book Value/Share $35.30
Revenue/Share $40.68
FCF/Share $9.24
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Johnson & Johnson converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Johnson & Johnson: An ROE of 31.6% demonstrates excellent shareholder value creation.

ROE 31.6%
ROA 13.4%
Gross Margin 71.3%
Net Margin 22.2%
EBT Margin 29.4%
Tax Rate 24.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Johnson & Johnson's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Johnson & Johnson: A current ratio of 1.09 shows adequate liquidity.

Current Ratio 1.09x
Quick Ratio 0.81x
D/E Ratio 1.37x
Financial Leverage 2.37x
Interest Coverage 42.2x
Working Capital $4.88B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Johnson & Johnson's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Johnson & Johnson: Free cash flow of $22244M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $24.76B
Free Cash Flow $22.24B
Capital Spending -$2.52B
FCF Growth YoY 25.1%
FCF/Sales 22.7%
CapEx/Sales 2.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Johnson & Johnson uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Johnson & Johnson: An asset turnover of 0.49x suggests room for improvement in asset utilization.

Asset Turnover 0.49x
Receivables Turnover 5.1x
Inventory Turnover 2.3x
Fixed Assets Turnover 4.2x
Days Sales Outstanding 71 days
Days Inventory 159 days
Payables Period 97 days
Cash Conversion Cycle 133 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Johnson & Johnson's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Johnson & Johnson: With annual revenue of $97929M, Johnson & Johnson operates at significant scale.

Income Statement
Total Revenue $97.93B
Net Income $26.86B
R&D Expense $12.62B
SG&A Expense $37.62B
Cost of Goods Sold $34.80B
Balance Sheet Highlights (% Of Assets)
Total Current Assets 59774%
Cash & Short-term Investments 20422%
Total Liabilities 116090%
Short-term Debt 45672%
Accounts Receivable 19046%
Inventory 15144%
Dividend & Shareholder Information
Dividends Per Share $5.24
Payout Ratio 0.6%
Shares Outstanding 2407M
Growth Metrics (YoY)
Net Income Growth 22.2%
EPS Growth 3.6%

Latest Johnson & Johnson Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Johnson & Johnson (JNJ) stock price and investment outlook.

📰 Loading...

Johnson & Johnson Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Johnson & Johnson against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AARD ██% $140M x 1.6x
ABBV ██% $466.15B 128.2x x
ABCL ██% $1.61B x 1.7x
ABEO ██% $342M 5.2x 2.4x
ABT ██% $186.84B 29.8x 3.6x
ABUS ██% $869M 5.4x 3.3x
ABVC ██% $27M x 2.5x
ABVX ██% $9.76B x x
ACAD ██% $4.45B 11.9x 3.6x
ACET ██% $77M x 0.6x
ACRS ██% $744M x 5.2x
ACRV ██% $60M x 0.6x
ACUT ██% $4M x x
ACXP ██% $6M x 0.9x
ADAG ██% $246M x 6.5x
ADCT ██% $141M x x
ADIL ██% $6M x 1.7x
ADTX ██% $3M x x
ADXN ██% $7M x x
AEON ██% $11M x x
AGIO ██% $2.14B x 1.9x
AKBA ██% $340M x 12.4x
AKTX ██% $15M x 1.0x
ALDX ██% $95M x 2.3x
ALKS ██% $8.46B 128.0x 4.7x
ALLR ██% $19M x 2.7x
ALMS ██% $3.38B x 6.0x
ALNY ██% $38.18B 121.7x 48.4x
ALT ██% $581M x 2.1x
ALXO ██% $268M x 1.8x
ALZN ██% $5M x 6.8x
AMLX ██% $2.17B x 8.0x
AMPH ██% $899M 11.4x 1.2x
AMRN ██% $293M x 0.7x
AMRX ██% $5.93B 48.6x x
ANAB ██% $1.51B x 118.7x
ANEB ██% $14M x 1.7x
ANIP ██% $1.69B 18.4x 3.0x
ANIX ██% $119M x 8.3x
ANNX ██% $757M x 3.7x
ANRO ██% $961M x 4.0x
ANTX ██% $169M x 2.1x
ANVS ██% $72M x 23.0x
APLM ██% $40M x x
APRE ██% $7M x 0.2x
APUS ██% $12M x 0.1x
APVO ██% $5M x 0.4x
AQST ██% $467M x x
ARCT ██% $163M x 0.9x
ARDX ██% $1.26B x 8.5x
ARQT ██% $3.55B x 18.7x
ARTL ██% $3M x 0.5x
ARVN ██% $529M x 1.4x
ARWR ██% $12.06B x 19.6x
ASBP ██% $9M x 2.4x
ASMB ██% $507M x 2.6x
ASND ██% $15.77B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.66B x 16.6x
ATHE ██% $83M x x
ATNM ██% $27M x 11.8x
ATOS ██% $24M x 0.8x
ATXI ██% $990K x 0.8x
AUPH ██% $1.96B 6.6x 3.5x
AVBP ██% $1.36B x 4.2x
AVIR ██% $361M x 1.5x
AVTX ██% $1.03B x 15.1x
AXIM ██% $1M x x
AXSM ██% $12.04B x 220.6x
AZTR ██% $2M x 0.2x
BBIO ██% $16.74B x x
BBOT ██% $688M x 1.9x
BCAX ██% $1.76B x 3.4x
BCTX ██% $30M x 1.3x
BCYC ██% $275M x 0.5x
BDPT ██% $30K x x
BDRX ██% $1M x x
BFRG ██% $11M x 2.2x
BFRI ██% $13M x 2.2x
BHC ██% $1.69B x x
BHST ██% $46M x 1.8x
BIOA ██% $973M x 2.6x
BIOE ██% $13M 9.7x x
BIOM ██% $380K x x
BIVI ██% $10M x 0.6x
BIXT ██% $3M x x
BLRX ██% $13M x x
BLTE ██% $6.14B x 8.0x
BMEA ██% $90M x 4.8x
BMRN ██% $12.00B 44.6x 1.9x
BMY ██% $129.62B 17.8x 6.5x
BNTC ██% $408M x 2.2x
BOLD ██% $55M x 0.6x
BOLT ██% $8M x 0.4x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $23M x 0.4x
BSPK ██% $10K x x
BTAI ██% $26M x x
BYSI ██% $49M x x
CALC ██% $11M x x
CANF ██% $7M x 1.2x
CAPR ██% $379M x 1.4x
CATX ██% $327M x 0.9x
CBIO ██% $626M x 6.2x
CDT ██% $2M x x
CING ██% $61M x 3.2x
CLCS ██% $65M x x
CLNN ██% $64M x x
CLRB ██% $20M x 5.9x
CLSDQ ██% $1M x x
CLYM ██% $732M x 5.0x
CMMB ██% $10M x 0.8x
CMND ██% $2M x x
CMPS ██% $1.52B x 4.7x
CNBX ██% N/A x x
CNSP ██% $7M x 104.8x
CNTA ██% $6.27B x 12.9x
CNTB ██% $132M x 3.1x
CNTX ██% $57M x 1.1x
COCP ██% $13M x 3.2x
COGT ██% $6.91B x 11.4x
COLL ██% $1.16B 15.5x 3.7x
CORT ██% $9.52B 201.0x 14.9x
COYA ██% $100M x 2.0x
CPHI ██% $50M x 1.4x
CPIX ██% $103M x 4.8x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $161M x 1.3x
CRMD ██% $596M 3.3x 1.4x
CRNX ██% $8.83B x 6.9x
CRVO ██% $25M x 2.3x
CRVS ██% $1.09B x 4.5x
CTMX ██% $708M x 2.2x
CTNM ██% $518M x 2.1x
CTOR ██% $52M x 1.5x
CTTH ██% $4M x 5.3x
CTXR ██% $14M x 0.2x
CUE ██% $131M x 6.1x
CURX ██% $5M x 0.6x
CVKD ██% $6M x 3.6x
CVSI ██% $4M x 2.6x
CYCN ██% $15M x 2.2x
CYDY ██% $270M x x
CYPH ██% $67M x 0.8x
CYRX ██% $766M 9.6x 1.6x
CYTK ██% $10.95B x x
DARE ██% $19M x 26.2x
DCOY ██% $2M x 0.5x
DERM ██% $174M x 5.6x
DMAC ██% $363M x 7.7x
DMRA ██% $1.80B x 3.5x
DNTH ██% $5.70B x 4.8x
DRMA ██% $5M x 0.8x
DRUG ██% $706M x x
DSGN ██% $742M x 3.4x
DWTX ██% $51M x 0.6x
DYN ██% $4.23B x 4.9x
EBS ██% $380M x 0.7x
EDSA ██% $48M x 4.7x
ELAB ██% $4M x 0.3x
ELAN ██% $12.69B x 2.0x
ELDN ██% $271M x 6.1x
ELTP ██% $409M 9.1x 4.1x
ELTX ██% $79M x x
ELVN ██% $3.77B x 8.3x
EMMA ██% $820K x x
ENLV ██% $72M 0.0x 0.0x
ENSC ██% $4M x x
ENTA ██% $370M x 3.2x
ENVB ██% $5M x 1.1x
EOLS ██% $401M x x
EPRX ██% $403M x 4.9x
EQ ██% $149M x 2.5x
ERAS ██% $6.55B x 16.6x
ERNA ██% $5M x 0.7x
ESPR ██% $799M x x
ETON ██% $1.16B x 37.8x
ETST ██% $35M 7.2x 5.0x
EVFM ██% $1M x x
EVMN ██% $413M x 1.4x
EWTX ██% $4.35B x 8.8x
FBIO ██% $109M 0.9x 0.7x
FBLG ██% $3M x 1.3x
FBRX ██% $1.57B x 37.3x
FHTX ██% $305M x x
FLNA ██% $44M x 0.6x
FTH ██% $754M x x
FULC ██% $248M x 0.7x
GALT ██% $223M x x
GANX ██% $79M x 5.6x
GCAN ██% $260K x x
GDTC ██% $11M x x
GERN ██% $956M x 4.2x
GHRS ██% $1.73B x x
GLMD ██% $3M x 0.2x
GLSI ██% $197M x 37.4x
GNLX ██% $132M x 5.8x
GNPX ██% $4M x 0.2x
GOSS ██% $97M x x
GOVX ██% $4M x 2.3x
GPCR ██% $3.46B x 2.4x
GRCE ██% $38M x 0.6x
GRI ██% $2M x 0.2x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $104.11B x x
GTBP ██% $12M x 1.6x
GYRE ██% $683M x 6.8x
HCM ██% $1.92B 2.1x 1.6x
HCWB ██% $4M x 0.8x
HELP ██% $477M x x
HEPA ██% $1M x 0.7x
HIND ██% $14M x 2.1x
HOOK ██% $14M x 0.4x
HOWL ██% $22M x 1.8x
HRMY ██% $2.06B 14.2x 2.3x
HRTX ██% $87M x 9.6x
HSTC ██% $99M x 79.9x
HURA ██% $141M x 6.1x
HYFT ██% $67M x x
HYPD ██% $39M x 0.7x
IBIO ██% $72M x 0.9x
IBO ██% $47M x 4.1x
IDYA ██% $3.16B x 3.4x
IFRX ██% $250M x x
IGC ██% $26M x 4.2x
IMMP ██% $56M x x
IMMX ██% $619M x 7.3x
IMNM ██% $2.56B x 4.3x
IMNN ██% $6M x 1.8x
IMRN ██% $9M x x
IMRX ██% $282M x 1.4x
IMUX ██% $188M x 1.2x
INBP ██% $5M x 0.3x
INDP ██% $272M x 217.8x
INDV ██% $4.96B 19.7x x
INM ██% $9M x 1.3x
INO ██% $80M x 13.2x
INSM ██% $22.68B x 32.2x
INTI ██% $14M x x
INVA ██% $1.62B 3.2x 1.2x
IOBTQ ██% $70K x 0.1x
IONS ██% $9.28B x 18.9x
IRD ██% $277M x x
IRON ██% $2.82B x 4.1x
IRWD ██% $644M 6.3x x
ISCO ██% $2M x x
IVA ██% $1.09B x x
IXHL ██% $36M x 0.5x
JAGX ██% $5M x x
JANX ██% $948M x 1.0x
JAZZ ██% $15.81B 536.1x 3.5x
JBIO ██% $1.21B x 4.1x
JNJ ██% $640.25B 30.4x 7.5x
JUNS ██% $6M x x
KALA ██% $12M x 1.2x
KALV ██% $1.38B x x
KAPA ██% $7M x 1.3x
KAYS ██% $210K x x
KMDA ██% $403M x x
KNSA ██% $4.86B 66.5x 8.0x
KPRX ██% $10M x 0.7x
KPTI ██% $160M x x
KROS ██% $201M x 0.7x
KRRO ██% $155M x 1.3x
KTTA ██% $15M x 0.3x
KURA ██% $825M x 7.6x
KYNB ██% $29M 0.2x x
LAB ██% $300M 3.8x 0.5x
LBRX ██% $997M x 2.6x
LEGN ██% $3.73B x x
LEXX ██% $13M x 2.7x
LFCR ██% $163M x x
LFVN ██% $80M 10.2x 2.4x
LGND ██% $5.96B 38.8x 6.0x
LGVN ██% $19M x 1.2x
LIANY ██% $12M x 0.1x
LIFD ██% $3M x 0.4x
LIPO ██% $150K x 0.1x
LITS ██% $34M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.85B x x
LLY ██% $1.09T 43.3x 35.1x
LNAI ██% $10M x x
LPCN ██% $16M x 0.7x
LQDA ██% $7.46B 334.2x 68.7x
LRMR ██% $394M x 2.5x
LSTA ██% $13M x 1.2x
LTRN ██% $36M x 10.3x
LXRX ██% $994M x 4.9x
LYEL ██% $302M x 1.1x
MAIA ██% $78M x 2.8x
MANE ██% $4.65B x 11.9x
MBIO ██% $4M x 0.5x
MBRX ██% $15M x 1.0x
MBX ██% $2.92B x 6.7x
MCRB ██% $47M x 1.8x
MDCX ██% $18M x 13.6x
MDGL ██% $12.70B x 23.4x
MGNX ██% $254M x 12.0x
MIRA ██% $37M x 4.0x
MIRM ██% $6.96B x 28.7x
MIST ██% $133M x 3.7x
MLTX ██% $1.69B x 6.7x
MLYS ██% $2.24B x 3.5x
MNKD ██% $1.22B x x
MNOV ██% $65M x 1.7x
MNPR ██% $739M x 5.5x
MPLT ██% $448M x 1.1x
MREO ██% $48M x 1.4x
MRK ██% $323.24B 36.2x 7.1x
MRKR ██% $20M x 1.5x
MRVI ██% $2.47B x 11.7x
MSLE ██% $197M x x
MTNB ██% $2M x 0.7x
MTVA ██% $7M x 0.8x
NAMS ██% $3.52B x 5.3x
NATR ██% $362M 18.2x 2.2x
NBP ██% $206M x 0.8x
NBTX ██% $1.95B x x
NCEL ██% $19M x 35.7x
NCNA ██% $5M x x
NERV ██% $184M x x
NEUP ██% $21M x 0.7x
NGNE ██% $691M x 2.9x
NIKA ██% $806M x x
NKTR ██% $2.41B x 4.2x
NKTX ██% $168M x 0.6x
NMAD ██% $81M x 10.2x
NNVC ██% $39M x 4.3x
NRIX ██% $2.43B x 6.0x
NRSN ██% $21M x x
NRXP ██% $155M x x
NSRX ██% $36M x 13.1x
NTHI ██% $85M x x
NUVB ██% $2.31B x 7.2x
NUVL ██% $9.75B x 8.3x
NVCT ██% $616M x 43.3x
NVS ██% $297.88B x x
NWBO ██% $273M x x
NXTC ██% $21M x 0.8x
NXTS ██% $2M x 0.2x
OCUL ██% $1.89B x 3.3x
OGEN ██% $2M x 0.4x
OGI ██% $132M x x
OGN ██% $3.56B 14.5x 3.9x
OKUR ██% $164M x 0.9x
OLMA ██% $1.05B x 2.2x
OMER ██% $816M 9.5x x
ONC ██% $33.81B 65.9x 7.1x
ONCO ██% $3M x 0.3x
ONCY ██% $93M x x
OPK ██% $937M x 0.8x
ORGO ██% $328M 120.7x 1.3x
ORIC ██% $1.24B x 3.0x
ORKA ██% $5.44B x 11.2x
ORMP ██% $170M 1.6x 0.7x
OSTX ██% $70M x x
OTLC ██% $18M x 0.1x
OVID ██% $439M x 2.2x
OWPC ██% $70K x x
PAHC ██% $1.43B 15.0x 4.0x
PBH ██% $2.44B 12.8x 1.3x
PBM ██% $12M x x
PBYI ██% $407M 16.7x 3.2x
PCRX ██% $1.04B 202.5x 1.6x
PCSA ██% $7M x 2.7x
PCYN ██% $2M x 1.0x
PDSB ██% $39M x 9.9x
PEPG ██% $131M x 1.0x
PFE ██% $140.40B 18.7x 1.6x
PGEN ██% $1.93B x 95.3x
PHAT ██% $949M x x
PHIO ██% $12M x 0.7x
PHVS ██% $2.37B x x
PKTX ██% $3M x 10.3x
PLRX ██% $67M x 0.4x
PLYX ██% $93M x 37.3x
PMHS ██% $2M x x
PMN ██% $105M x 1.7x
PMVP ██% $63M x 0.7x
PPBT ██% $1M x x
PPCB ██% $3M x 0.3x
PRAX ██% $8.80B x 6.2x
PRFX ██% $3M x 0.4x
PRGO ██% $1.40B x 0.6x
PRLD ██% $321M x 5.3x
PRPH ██% $840K x 0.1x
PRQR ██% $244M x x
PRTA ██% $462M x 1.5x
PTCT ██% $6.28B x x
PTGX ██% $8.71B x 13.3x
PTIX ██% $420K x x
PTN ██% $14M x 1.3x
PTPI ██% $170K 0.0x 0.1x
PULM ██% $6M x 1.8x
PVCT ██% $25M x x
PVLA ██% $2.03B x 8.7x
PYXS ██% $183M x 5.9x
QNRX ██% $9M x 1.0x
QNTM ██% $19M x x
QTTB ██% $452M 13.6x 9.8x
QUCY ██% $25M x 5.5x
QURE ██% $2.41B x 16.1x
RADX ██% $29M x x
RANI ██% $111M x 3.9x
RAPP ██% $2.01B x 4.3x
RARE ██% $2.64B x x
RCKT ██% $355M x 1.5x
RCUS ██% $3.49B x 6.7x
RDY ██% $9.82B x x
REGN ██% $69.39B 15.7x 2.2x
REVB ██% $4M x 0.3x
RFL ██% $121M x 1.6x
RGBP ██% $50K x x
RIGL ██% $688M 1.9x 1.7x
RKTO ██% $17M x 4.1x
RLMD ██% $546M x 2.5x
RLYB ██% $86M x 1.7x
RMHI ██% $25M x x
RMTI ██% $29M x 0.8x
RNAC ██% $212M x x
RNAZ ██% $5M x 4.0x
RNTX ██% $67M x 5.8x
RNXT ██% $42M x 3.7x
ROIV ██% $25.01B x 5.5x
RPRX ██% $33.82B 40.9x 4.9x
RTEZ ██% $1.93B x x
RVPH ██% $7M x 0.4x
RVRC ██% $101M x 16.5x
RYTM ██% $7.26B x 59.1x
RZLT ██% $478M x 4.1x
SBFM ██% $2M x 0.1x
SCNX ██% $15M x 0.2x
SCYX ██% $284M x 6.9x
SDEV ██% $30M 0.1x 0.2x
SDGR ██% $1.13B x 3.6x
SEPN ██% $1.50B x 4.0x
SER ██% $31M x 1.8x
SGMT ██% $460M x 4.5x
SHPH ██% $2M x 0.5x
SIGA ██% $222M 11.0x 1.5x
SILO ██% $5M x 0.9x
SION ██% $2.05B x 7.1x
SKVI ██% $1M x x
SKYE ██% $22M x 2.4x
SLGL ██% $259M x 11.4x
SLN ██% $570M x 11.5x
SLS ██% $1.97B x 18.3x
SMMT ██% $10.39B x 16.5x
SMNR ██% $145M x x
SNDX ██% $1.80B x 43.1x
SNGX ██% $5M x 1.7x
SNSE ██% $31M x x
SNY ██% $108.63B x x
SPRB ██% $116M x 3.3x
SPRC ██% $3M x x
SPRO ██% $70M 4.6x 1.3x
SPRY ██% $572M x 9.3x
SRPT ██% $1.67B 25.8x 1.1x
STOK ██% $1.85B x 4.7x
STTK ██% $670M x 7.0x
SUPN ██% $2.73B x 2.5x
SVRA ██% $1.10B x 6.2x
SXTP ██% $4M x 0.8x
SYBX ██% $7M x 0.6x
SYRE ██% $7.58B x 11.3x
TAK ██% $56.43B x x
TBPH ██% $870M 7.6x 3.0x
TCRT ██% $4M x 3.5x
TELO ██% $82M x 16.5x
TENX ██% $411M x 3.6x
TEVA ██% $36.52B 23.3x 4.4x
TGTX ██% $8.54B 18.5x 14.7x
TLPH ██% $63M x 3.4x
TLX ██% $3.41B x x
TNGX ██% $4.16B x 10.6x
TNXP ██% $161M x 0.7x
TOVX ██% $10M x 0.6x
TPST ██% $15M x 17.9x
TRDA ██% $228M x 0.8x
TRVI ██% $2.32B x 13.5x
TTRX ██% $238M x 38.9x
TVRD ██% $23M x 1.6x
TVTX ██% $5.16B x 52.2x
TXMD ██% $24M 131.9x 0.9x
TYRA ██% $1.85B x 4.8x
UNCY ██% $126M x 3.4x
UPB ██% $333M x 1.1x
URGN ██% $1.99B x x
UTHR ██% $26.28B 20.4x 4.5x
VBIO ██% $890K x 0.1x
VCNX ██% $3M x x
VERA ██% $2.40B x 4.8x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $3.84B x 7.6x
VNDA ██% $308M x 1.1x
VRCA ██% $99M x 6.2x
VRDN ██% $1.99B x 3.1x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $122.80B 28.3x 6.3x
VSTM ██% $542M x 6.6x
VTGN ██% $9M x 0.3x
VTRS ██% $20.60B x 1.4x
VYNE ██% $19M x 0.8x
WHWK ██% $166M x 1.4x
WVE ██% $1.13B x 2.2x
XBIO ██% $6M x 0.8x
XBIT ██% $70M x 0.5x
XCUR ██% $10M x 5.0x
XENE ██% $6.29B x 4.7x
XERS ██% $1.43B 118.9x 109.8x
XLO ██% $60M x 0.8x
XNCR ██% $1.44B x 2.8x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $7M x x
ZBIO ██% $2.03B x 6.0x
ZLAB ██% $2.10B x 3.2x
ZNTL ██% $322M x 1.8x
ZTS ██% $32.57B 12.3x 10.1x
ZVRA ██% $568M 4.6x 2.8x
ZVSA ██% $940K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Johnson & Johnson Stock Forecast

How accurate are Johnson & Johnson stock predictions?

Our AI model shows a -1% Spearman correlation coefficient for JNJ predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Johnson & Johnson stock price forecasts?

Our analysis considers Johnson & Johnson's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Johnson & Johnson a good investment in 2025?

Based on our AI analysis, Johnson & Johnson shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Johnson & Johnson forecasts updated?

Johnson & Johnson stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Johnson & Johnson?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...